amphotericin B liposome

JM037 is a liposomal formulation of the polyene antifungal agent amphotericin B, developed by Zhejiang Jimin Pharmaceutical as a generic version of the reference drug AmBisome. The liposomal delivery system is designed to improve the safety profile of amphotericin B by reducing its distribution to the kidneys, thereby minimizing nephrotoxicity, which is a common dose-limiting side effect of conventional amphotericin B deoxycholate. Amphotericin B works by binding to ergosterol, a key component of fungal cell membranes, leading to the formation of transmembrane pores. These pores cause the leakage of essential intracellular ions and molecules, ultimately resulting in fungal cell death. JM037 is primarily indicated for the treatment of severe systemic fungal infections, including aspergillosis, candidiasis, and cryptococcal meningitis, and is also used for empirical therapy in patients with febrile neutropenia.

Other names

amphotericin B liposome for injection